Key

Inclusion Criteria:

- Pathologically or cytologically documented advanced solid tumor that is refractory to
standard treatment, for which no standard therapy is available, or the patient
refuses standard therapy.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

- Men or women at least 18 years of age

- Adequate hematologic, cardiac, renal, hepatic, metabolic, and coagulation function

Key Exclusion Criteria:

- Presence of untreated or symptomatic brain metastasis.

- Presence of ascites or pleural effusion requiring chronic medical intervention.

- Uncontrolled hypertension

- Concurrent or previous (within 1 week of study day 1) anticoagulation therapy, except
low-dose warfarin (≤ 2 mg/day) or low dose,low molecular weight heparin for
prophylaxis against central venous catheter thrombosis.

- Recent major surgical procedure or not yet recovered from major surgery

- Recent participation in clinical drug trials.

- Participation in other investigational procedures.

- Unresolved toxicities from prior anti-cancer therapy

- Patient who is pregnant (e.g. positive human choriogonadotropin [HCG] test) or
nursing.